Status:
UNKNOWN
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Lead Sponsor:
King's College London
Conditions:
Muscle Invasive Bladder Cancer
Surgery
Eligibility:
All Genders
18+ years
Brief Summary
Through our study, we aim to understand the most important factors for patients when they decide on the type of treatment they receive for MIBC. Our study consists of a discrete choice experiment (DCE...
Detailed Description
The study will be conducted using validated and established protocols for undertaking DCEs. A literature review was undertaken to assess what the most important considerations where for patients when ...
Eligibility Criteria
Inclusion
- Diagnosed with MIBC cancer and currently undergoing treatment or have previously completed treatment for MIBC
Exclusion
- Any of other type of bladder cancer (unknown, metastatic, or non muscle invasive bladder cancer)
Key Trial Info
Start Date :
July 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05236218
Start Date
July 20 2022
End Date
January 1 2024
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom